Sep 11, 2026 04:30PM
Mar 27, 2026 05:00PM
Mar 9, 2026 08:30AM
Mar 9, 2026 08:30AM
Feb 19, 2026 07:30AM
Feb 19, 2026 07:30AM
Sep 12, 2025 08:30AM Interim results for the six months ended June 30, 2025
Sep 8, 2025 07:01AM
Sep 8, 2025 07:00AM
Jul 28, 2025 07:00AM
Jul 28, 2025 07:00AM
Jul 14, 2025 08:31AM
Jul 14, 2025 08:30AM
Jun 18, 2025 07:02AM Biodexa Pharmaceuticals (BDRX) Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
Jun 18, 2025 07:00AM
May 12, 2025 08:31AM
May 12, 2025 08:30AM
Apr 11, 2025 08:30AM
Mar 19, 2025 07:04AM
Mar 19, 2025 07:00AM
Mar 10, 2025 08:31AM Biodexa Pharmaceuticals (BDRX) Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
Mar 10, 2025 08:30AM
Feb 24, 2025 08:30AM
Feb 12, 2025 07:30AM
Feb 10, 2025 08:30AM
Feb 10, 2025 08:30AM
Nov 21, 2024 07:35AM
Oct 17, 2024 07:34AM Biodexa Pharmaceuticals' (BDRX) MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
Oct 17, 2024 07:30AM
Sep 26, 2024 08:30AM
Jul 11, 2024 08:32AM
Jul 11, 2024 08:30AM
Jun 3, 2024 08:00AM
May 9, 2024 08:00AM
Apr 26, 2024 08:31AM Biodexa Pharmaceuticals (BDRX) Enters Exclusive License to eRapa
Apr 26, 2024 08:30AM
Apr 26, 2024 08:30AM
Apr 19, 2024 08:00AM
Mar 28, 2024 08:18AM
Mar 28, 2024 08:15AM
Mar 1, 2024 08:00AM
Jan 22, 2024 08:30AM Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

332,701 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All